A small group of lung cancer patients, who carry EML4-ALK marker in their tumor genome, can now look forward to a cancer-free future, thanks to a new drug crizotinib being developed by Pfizer. This group of patients are generally nonsmokers or had given up smoking long ago, but still have the misfortune of coming down with lung cancer.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label alk. Show all posts
Showing posts with label alk. Show all posts
Wednesday, June 8, 2011
Sunday, March 20, 2011
Diagnostic Trailblazers in San Diego Advancing CDx, PGx and PM Goals in Cancer
Yesterday, I attended a half day symposium on companion diagnostics (CDx) efforts in San Diego which was organized by the SABPA Science & Technology Forum. CDx is the identification and detection of biomarkers to predict whether a drug will work or not in a given patient. Two successful marketed products are HercepTest (marketed by Dako) for Herceptin and KRAS tests for Erbitux and Vectibix. San Diego biotech has a rich history and deep investments in diagnostics. This was reflected in the lineup of various talks.
Subscribe to:
Posts (Atom)